利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

1013 条记录 (耗时 0.024 秒)

    Treatment of hypercoagulopathy in Cushing's syndrome by administration of glucocorticoid receptor modulators
    1.
    发明授权
    Treatment of hypercoagulopathy in Cushing's syndrome by administration of glucocorticoid receptor modulators 有权

    公开(公告)号：US12102642B2

    公开(公告)日：2024-10-01

    申请号：US17983971

    申请日：2022-11-09

    申请人： Corcept Therapeutics Incorporated

    发明人： Andreas G. Moraitis

    IPC分类号： A61K31/567 ,  A61P7/04 ,  G01N33/74

    CPC分类号： A61K31/567 ,  A61P7/04 ,  G01N33/743

    摘要： Novel methods for preventing, reducing the risk of development of, and for treating hypercoagulopathy in Cushing's syndrome patients with elevated risk of developing hypercoagulopathy are disclosed. The methods are further useful to prevent, to reduce the risk of developing, and to treat deep vein thrombosis (DVT), pulmonary embolism (PE), and venous thromboembolism (VTE); and to treat inflammatory states.
    The methods include: administering heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator (HKGRM) to a Cushing's syndrome patient at risk of developing hypercoagulopathy, thereby treating hypercoagulopathy. Methods of preventing, reducing risk of developing, and of treating DVT, PR, or VTE in a Cushing's syndrome patient comprise administering a HKGRM to the patient. Methods of unmasking and subsequently reducing an inflammatory state comprise administering an effective amount of a HKGRM to a Cushing's syndrome patient, effective first to increase inflammatory symptoms and then to subsequently decrease said inflammatory symptoms in the patient.

    Screening Kit and Diagnosis System for Primary Aldosteronism
    3.
    发明公开
    Screening Kit and Diagnosis System for Primary Aldosteronism 审中-公开

    公开(公告)号：US20240019449A1

    公开(公告)日：2024-01-18

    申请号：US18304915

    申请日：2023-04-21

    申请人： Hangzhou Calibra Diagnostics Co., Ltd.

    发明人： Pengyun LIU ,  Xiaofen YUAN ,  Jinfei MA ,  Ziqing KONG ,  Yikun LI ,  Weijia WU ,  Huafen LIU

    IPC分类号： G01N33/74 ,  G01N33/68 ,  G01N1/34

    CPC分类号： G01N33/743 ,  G01N33/6848 ,  G01N1/34

    摘要： In a screening kit and a confirmed and typing diagnosis system for primary aldosteronism, a sample is pretreated by a magnetic bead bonded with a balanced hydrophilic-lipophilic polymer on the surface thereof, and process conditions are optimized and the content of each the five markers such as, aldosterone in the sample is accurately detected by liquid chromatography-tandem mass spectrometry for one time, thus finding the optimal screening cut-off value of 20.4; when a positive result is judged, PA is confirmed and subjected to typing diagnosis according to the test values of the markers, thereby achieving the simultaneous detection of the content of each the five markers such as, aldosterone on the same platform. Therefore, the screening kit and confirmed and typing diagnosis system for primary aldosteronism are integrated with screening, confirmed and typing diagnosis functions, thus providing a reliable laboratory examination basis for clinicians to formulate an effective therapeutic regimen.